Aromando Andrew
Chief Business Officer
Aromando Andrew has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 13, 2026.
On the most recent filing, Aromando Andrew is listed as Chief Business Officer at ONCOLYTICS BIOTECH INC. Inside the rolling window, Aromando Andrew reported 1 open-market purchase totaling $25K in ONCY and no open-market sales.
Companies traded
Other insiders at ONCY
Insider Buying
$25K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Aromando Andrew made?
Aromando Andrew has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Aromando Andrew trade?
Aromando Andrew has filed SEC Form 4 disclosures for 1 company, including ONCY.
When was Aromando Andrew's most recent SEC Form 4 filing?
Aromando Andrew's most recent SEC Form 4 filing on Tracefour is dated Feb 13, 2026.
What is Aromando Andrew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Aromando Andrew is listed as Chief Business Officer.
What is Aromando Andrew's total buy and sell value in the current window?
Inside the rolling retention window, Aromando Andrew bought $25K and sold $0 based on SEC Form 4 filings.
What was Aromando Andrew's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 29,600 ONCY shares on 2026-02-11, worth $25K, per SEC Form 4 filings.